Here is STAT’s Biotech Scorecard, our regular ledger of stock-moving biotech events, for the first quarter.
It’s rare to include a new drug submission to the Food and Drug Administration in the quarterly scorecard. With that said, any development regarding Biogen’s (BIIB) controversial Alzheimer’s drug aducanumab is significant enough to matter. Biogen has told investors that it will complete the aducanumab filing to the FDA in “early 2020” — which sounds like the first quarter.
I do not want to subscribe. Please remove my name from your subscribe list. Thank you
Comments are closed.